AZ's MedImmune Links With Inovio Cancer Vaccine
This article was originally published in Scrip
Executive Summary
AstraZeneca's MedImmune unit has licensed a cancer vaccine from Inovio for potential use with some of its immunotherapy drug candidates in yet another deal in the immune-oncology (IO) space.